innoVitro awarded as most innovative in vitro technology company in Germany

innoVitro has been recognized by GHP (Global Health & Pharma) as most innovative in vitro technology company in Germany for the year 2022. Read the interview with Matthias Gossmann, CEO of innoVitro hereContinue readinginnoVitro awarded as most innovative in vitro technology company in Germany

News

innoVation Series April – May 2022

The article from Chirikian et al., 2022 covering April and May of the innoVation Series addresses the effects of xeno-free cryopreservation on the contractile properties of human iPSC-derived cardiomyocytes. Read the article to find out about alterations in both the contractile and calcium handling properties of xeno-free cryopreserved hiPSC-CMs. Collectively, the authors observed increased force…Continue readinginnoVation Series April – May 2022

News

Meet us at the XVIth International Congress of Toxicology (ICT), September 18 – 21, 2022 in Maastricht, Netherlands.

Meet us at the innoVitro Booth 51 in Maastrichts Expositie en Congres Centrum (MECC), September 18th – 21st, 2022. We will also present a poster (No 456) entitelt “Chronic Compound Analysis of hiPSC-CMs in a Physiological Environment for Preclinical Cardiac Risk Evaluation: Defined Serum-Free Medium and Long-Term Culture on the FLEXcyte 96”. We are looking…Continue readingMeet us at the XVIth International Congress of Toxicology (ICT), September 18 – 21, 2022 in Maastricht, Netherlands.

News

Safety Pharmacology Society Annual Meeting, September 11 -14, 2022 in Montréal, Canada.

Meet us at the innoVitro Booth 810 in Montréal, Canada at the Safety Pharmacology Society Annual Meeting in September 2022! Don’t miss our poster presentations entitelt (SP090) “Lot-to-lot consistency study of commercial human iPSC derived cardiomyocytes regarding contractile properties” and (SP091) “Assessment of a Smooth Muscle Cell Maturation Protocol for the Analysis of Contractile Properties”.…Continue readingSafety Pharmacology Society Annual Meeting, September 11 -14, 2022 in Montréal, Canada.

News

Society of Toxicology Annual Meeting, San Diego, CA, March 27-31, 2022

Check out our poster entitled “Tackling human iPSC-cardiomyocte maturation in vitro for predictive nonclinical cardio-toxicological assessment” at the SOT poster session in collaboration with Nanion Technologies!Continue readingSociety of Toxicology Annual Meeting, San Diego, CA, March 27-31, 2022

News

innoVation Series – March 2022

In the March issue of the innovation Series a charcterization study of cardiac cells and their gene expression profiles was performed. Six anatomical adult heart regions were analyzed to establish a cardiac cell atlas for better understanding of the adult human heart. In detail, Litviňuková et al., 2022 highlight the cellular heterogeneity of cardiomyocytes, pericytes…Continue readinginnoVation Series – March 2022

News

innoVation Series – February 2022

A newly published article assessing human induced pluripotent stem cell derived-cardiomyocyte (hiPSC-CM) contractility kinetics caught our interest this month. The data shows that flexible substrates are necessary for normal twitch-like contractility kinetics and interpretation of inotropic interventions. Huethorst et al. analyzed spatiotemporal contractility of hiPSC-CM monolayers seeded on conventional, rigid surfaces (glass or plastic) and…Continue readinginnoVation Series – February 2022

News

innoVation Facts – Cardiac Maturation Cues (Part 3)

The last part of our innoVation Facts series dealing with cardiac maturation cues focused on gene expression analysis of human iPSC-derived cardiomyocytes (hiPSC-CMs) cultured either on physiological FLEXcyte or regular cell culture plates. The data shows increased expression levels of ACTC1 and ACTN2 genes (both producing cytoskeleton-related proteins) as well as the MYH7 gene (important…Continue readinginnoVation Facts – Cardiac Maturation Cues (Part 3)

News

innoVation Series – Research Article of the Month – January

We start the new year with an article by Lebrec et al., 2021 covering CAR-T / TCR immunotherapy research findings with a focus on nonclinical safety evaluation. Engineered T cell therapies provide huge opportunities to address current unmet medical needs but present also unique challenges in terms of safety assessment during nonclinical and clinical development.…Continue readinginnoVation Series – Research Article of the Month – January

News

Biophysical Society 66th Annual Meeting, February 19 -23, 2022

Meet us at the 66th Biophysical Society Meeting at the Moscone Center in San Francisco, California, USA. We will present new data on how to fascilitate cardiac maturation cues of human iPSC-derived cardiomyocytes for in vitro cardiac risk evaluation at Nanion Technologies exhibitor symposium taking place on Monday, 21st of February, 2022.Continue readingBiophysical Society 66th Annual Meeting, February 19 -23, 2022

News